Acrivon Therapeutics (ACRV) Institutional Ownership $1.52 -0.03 (-1.94%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.51 -0.01 (-0.66%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)CurrentInstitutional OwnershipPercentage71.62%Number ofInstitutional Buyers(last 12 months)18TotalInstitutional Inflows(last 12 months)$5.15MNumber ofInstitutional Sellers(last 12 months)12TotalInstitutional Outflows(last 12 months)$3.39M Get ACRV Insider Trade Alerts Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ACRV Institutional Buying and Selling by Quarter Acrivon Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Bridgeway Capital Management LLC22,900$27K0.0%-70.6%0.073% 8/14/2025 Jane Street Group LLC311,829$371K0.0%N/A0.995% 8/13/2025 Marshall Wace LLP181,187$216K0.0%-59.8%0.578% 8/13/2025 Quadrature Capital Ltd22,175$26K0.0%N/A0.071% 8/12/2025 XTX Topco Ltd106,119$126K0.0%N/A0.338% 8/8/2025 Geode Capital Management LLC164,362$196K0.0%-46.3%0.524% 6/27/2025 Goldman Sachs Group Inc.57,519$117K0.0%-75.8%0.183% 5/16/2025Goldman Sachs Group Inc.57,519$117K0.0%-75.8%0.183% 5/15/2025Baker BROS. Advisors LP22,809$46K0.0%-56.9%0.073% 5/13/2025Wealthedge Investment Advisors LLC56,467$115K0.1%+420.1%0.180% Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/12/2025Nuveen LLC13,402$27K0.0%N/A0.043% 5/12/2025Invesco Ltd.35,315$72K0.0%N/A0.113% 3/12/2025Wealthedge Investment Advisors LLC10,857$65K0.0%N/A0.035% 2/17/2025Nuveen Asset Management LLC13,402$81K0.0%-48.0%0.043% 2/17/2025OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC102,784$619K0.0%+29.7%0.330% 2/17/2025Corton Capital Inc.12,159$73K0.0%N/A0.039% 2/17/2025Bridgeway Capital Management LLC74,600$449K0.0%-3.1%0.240% 2/17/2025Citadel Advisors LLC2,119,646$12.76M0.0%-1.0%6.807% 2/17/2025Acorn Capital Advisors LLC405,237$2.44M1.3%N/A1.301% 2/14/2025Northern Trust Corp117,323$706K0.0%+11.3%0.377% 2/14/2025Dimensional Fund Advisors LP37,063$223K0.0%+20.2%0.119% 2/13/2025Marshall Wace LLP597,794$3.60M0.0%-26.2%1.920% 2/13/2025Barclays PLC38,091$228K0.0%+14.4%0.122% 2/13/2025Renaissance Technologies LLC49,400$297K0.0%+7.6%0.159% 2/12/2025Trexquant Investment LP16,871$102K0.0%-44.5%0.054% 2/12/2025JPMorgan Chase & Co.25,809$155K0.0%-24.1%0.083% 2/11/2025American Century Companies Inc.17,588$106K0.0%+14.2%0.056% 2/6/2025Charles Schwab Investment Management Inc.113,840$685K0.0%-2.1%0.366% 2/4/2025Bank of New York Mellon Corp27,635$166K0.0%-6.4%0.089% 1/24/2025China Universal Asset Management Co. Ltd.6,602$40K0.0%N/A0.021% 12/26/2024JPMorgan Chase & Co.33,991$238K0.0%+548.3%0.109% 12/13/2024Exome Asset Management LLC116,757$817K0.5%N/A0.375% 11/19/2024Barclays PLC33,306$233K0.0%+51.2%0.107% 11/16/2024Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975% 11/15/2024Barclays PLC33,306$233K0.0%+51.2%0.108% 11/15/2024State Street Corp225,896$1.58M0.0%+26.4%0.729% 11/12/2024Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375% 10/10/2024Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066% 8/16/2024Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362% 8/14/2024Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073% 8/13/2024Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874% 8/12/2024XTX Topco Ltd10,493$61K0.0%N/A0.034% 8/9/2024Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177% 8/9/2024Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033% 8/1/2024Rhumbline Advisers16,209$94K0.0%+48.9%0.052% 7/26/2024Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119% 5/15/2024Baker BROS. Advisors LP52,885$378K0.0%N/A0.234% 5/14/2024American International Group Inc.6,016$43K0.0%+39.2%0.027% 5/10/2024Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241% 1/5/2024Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060% 11/13/2023Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020% 9/21/2023Barclays PLC14,263$184K0.0%-16.0%0.065% 8/10/2023AAF Wealth Management LLC10,678$138K0.1%N/A0.049% 7/20/2023Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053% 5/8/2023Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798% 2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360% 2/14/2023RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028% 2/13/2023Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913% 2/10/2023NEA Management Company LLC481,677$4.44M0.2%N/A2.306% 2/1/2023Bank of Montreal Can42,444$545K0.0%N/A0.203% (Data available from 1/1/2016 forward) ACRV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACRV shares? During the previous two years, 35 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($31.09M), Citadel Advisors LLC ($12.76M), Sands Capital Ventures LLC ($12.31M), Vanguard Group Inc. ($3.63M), Acorn Capital Advisors LLC ($2.44M), Federated Hermes Inc. ($2.16M), and State Street Corp ($1.58M).Learn more on Acrivon Therapeutics' institutional investors. What percentage of Acrivon Therapeutics' stock is owned by institutional investors? 71.62% of Acrivon Therapeutics' stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings. Which institutional investors have been buying Acrivon Therapeutics' stock? Of the 27 institutional investors that purchased Acrivon Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($470K), Acorn Capital Advisors LLC ($405.24K), Marshall Wace LLP ($351.40K), Jane Street Group LLC ($311.83K), Exome Asset Management LLC ($116.76K), and XTX Topco Ltd ($116.61K). How much institutional buying is happening at Acrivon Therapeutics? Institutional investors have bought a total of 1,236,759 shares in the last 24 months. This purchase volume represents approximately $5.15M in transactions. Which of Acrivon Therapeutics' major shareholders have been selling company stock? Of the 12 institutional investors that sold Acrivon Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Marshall Wace LLP ($481.27K), Goldman Sachs Group Inc. ($360.07K), Geode Capital Management LLC ($148.04K), Bridgeway Capital Management LLC ($57.38K), Charles Schwab Investment Management Inc. ($30.12K), Baker BROS. Advisors LP ($30.08K), and Exchange Traded Concepts LLC ($22.52K). How much institutional selling is happening at Acrivon Therapeutics? Institutional investors have sold a total of 1,186,392 shares in the last 24 months. This volume of shares sold represents approximately $3.39M in transactions. Related Companies Nuvectis Pharma Institutional Ownership Seres Therapeutics Institutional Ownership Lifevantage Institutional Ownership Kyverna Therapeutics Institutional Ownership MEI Pharma Institutional Ownership Black Diamond Therapeutics Institutional Ownership Greenwich LifeSciences Institutional Ownership Milestone Pharmaceuticals Institutional Ownership Eledon Pharmaceuticals Institutional Ownership Molecular Partners Institutional Ownership This page (NASDAQ:ACRV) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.